Katharine Margaret Botelle Wolhart, MSW, LICSW | |
410 W. Bakerview Rd. Suite 110, Office 110, Bellingham, WA 98226-9822 | |
(360) 926-5647 | |
Not Available |
Full Name | Katharine Margaret Botelle Wolhart |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 410 W. Bakerview Rd. Suite 110, Bellingham, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003064817 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
1041C0700X | Social Worker - Clinical | LW00009583 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Katharine Margaret Botelle Wolhart, MSW, LICSW 26910 92nd Ave Nw Ste C5-203, Stanwood, WA 98292-5437 Ph: (360) 926-5647 | Katharine Margaret Botelle Wolhart, MSW, LICSW 410 W. Bakerview Rd. Suite 110, Office 110, Bellingham, WA 98226-9822 Ph: (360) 926-5647 |
News Archive
A bit of pressure from a new shrinking, sponge-like gel is all it takes to turn transplanted unspecialized cells into cells that lay down minerals and begin to form teeth.
Cancer researchers at the University of Bath have measured systematically how efficient molecules are at suppressing the activity of a protein associated with prostate and other cancers. The molecules could eventually be developed into new anti-cancer drugs.
A new study found that opioid prescription use is more common in cancer survivors than in individuals without a history of cancer.
Senesco Technologies, Inc. today announced the initiation of patient dosing in its Phase 1b/2a clinical study of SNS01-T at the Mayo Clinic in Rochester, MN. The study is an open-label, multiple-dose, dose-escalation study which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.
Colorectal cancer is a significant public health problem for which differing treatment regimes hold different benefits in associated efficacy, safety and tolerability, according to study findings showcased at the 13th European Cancer Conference (ECCO).
› Verified 1 days ago